(NASDAQ:BOLD), BBI-355 and BBI-825 combination arm of the POTENTIATE trial is now open for enrollment BBI-940 is on track for submission of an investigational new drug application in the first half of 2026 $127 million in cash supports operations into the first half of 2028, throughexpected proof-of-concept clinical readouts for both programs SAN DIEGO, Aug. […]

(NASDAQ:CBUS), SAN DIEGO, Aug. 05, 2025 (GLOBE NEWSWIRE) — Cibus, Inc. (Nasdaq: CBUS), a leading agricultural technology company that develops and licenses plant traits to seed companies, today announced that the company will report second quarter 2025 financial results on Thursday, August 14, 2025. Cibus' management team will host a conference call and audio webcast

(NASDAQ:EVGO), $225 million oversubscribed 5-year facility placed in July with five participating lenders and option to increase up to $300 million. Record revenue of $98.0 million in the second quarter, representing an increase of 47% year-over-year. Charging network revenue totaled a record $51.8 million in the second quarter, an increase of 46% year-over-year, representing the

(NasdaqGM:OBIO), $56.2 million in proceeds from completed public offering and concurrent private equity purchase by Medtronic and Ligand $55 million in proceeds and funding commitments from royalty-based, non-dilutive investments from Medtronic and Ligand Proceeds extend expected cash runway into the second half of 2027 and expected to fund completion of enrollment and follow up for

(NASDAQ:BEAM), With 17 Patients Dosed in the Phase 1/2 Trial, BEAM-302 Continues to Demonstrate Durable Correction of the Disease-causing Mutation, Restoration of AAT Physiology, and a Well Tolerated Safety Profile BEAM-302 Expanded Dose Exploration Underway in Part A and Enrollment Initiated in Part B; Data from Parts A and B of the Phase 1/2 Trial

(NYSE:NVRI), Second quarter revenues totaled $562 million Second quarter GAAP consolidated loss from continuing operations of $46 million Adjusted EBITDA in Q2 totaled $65 million 2025 Adjusted EBITDA now expected to be within a range of $290 million to $310 million and free cash flow expected to be within a range of $15 million to

J & J Snack Foods Reports Fiscal 2025 Third Quarter Results GlobeNewswire August 05, 2025 MOUNT LAUREL, N.J., Aug. 05, 2025 (GLOBE NEWSWIRE) — J & J Snack Foods Corp. (NASDAQ: JJSF) (the “Company”) today reported financial results for the third quarter ended June 28, 2025. Third Quarter Actuals $ vs. LY % vs. LY

FUNDAMENTAL GLOBAL INC. SUCCESSFULLY CLOSES $200 MILLION PRIVATE PLACEMENT TO ACCELERATE ETHEREUM TREASURY STRATEGY GlobeNewswire August 05, 2025 Net Proceeds Will Immediately Fund Ethereum (ETH) Acquisition Strategy Maja Vujinovic, an Early Blockchain Pioneer, to Lead the Digital Asset Business Fundamental Global Inc. to be Renamed FG Nexus Inc. Charlotte, NC, Aug. 05, 2025 (GLOBE NEWSWIRE)

Blade Air Mobility Announces Second Quarter 2025 Results GlobeNewswire August 05, 2025 Medical revenue increased 17.6% year-over-year in Q2 2025 Net loss improved by $7.6 million versus the prior year to $(3.7) million in Q2 2025; Adjusted EBITDA improved by $2.2 million versus the prior year to $3.2 million in Q2 2025(1) Blade Passenger division

(NasdaqGM:TNGX), – First patient dosed in combination trial of TNG462 and Revolution Medicines RAS(ON) inhibitors – – First patient dosed in Phase 1/2 trial with TNG456, a brain-penetrant MTA-cooperative PRMT5 inhibitor in development for glioblastoma – BOSTON, Aug. 05, 2025 (GLOBE NEWSWIRE) — Tango Therapeutics, Inc. (NASDAQ: TNGX), a clinical-stage biotechnology company committed to discovering